Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 39Ovarian Neoplasms 29Multiple Myeloma 16Neoplasms 9Recurrence 8Lymphoma 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Carcinoma, Ovarian Epithelial 7Lymphoma, Non-Hodgkin 6Sarcoma 5Neoplasm Metastasis 5Burkitt Lymphoma 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Leiomyosarcoma 2Kidney Neoplasms 2Endometrial Neoplasms 2Disease Progression 2Vulvar Neoplasms 1Vaginal Neoplasms 1

Interventions

Oxaliplatin 166Capecitabine 112Fluorouracil 95Docetaxel 85Cisplatin 84S 1 (combination) 83Leucovorin 64Paclitaxel 58Irinotecan 56pembrolizumab 36sintilimab 34Trastuzumab 34apatinib 30Bevacizumab 21Surgical Procedures, Operative 19Radiotherapy 19titanium silicide 17camrelizumab 17Nivolumab 17Ramucirumab 16Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 14Folfox protocol 14Epirubicin 14tislelizumab 13Neoadjuvant Therapy 12Cetuximab 12XELOX 10Tegafur 10Carboplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Stomach Neoplasms × liposomal doxorubicin × Clear all
NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡